Listed

Kiora Pharmaceuticals Inc: Form 10-Q for the period ended Mar 31, 2018

Filed with the SEC on May 11, 2018 and accepted by EDGAR at May 11, 2018, 08:21 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2018-01-01 to 2018-03-31$2.5mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2018-01-01 to 2018-03-31−$2.4mus-gaap:OperatingIncomeLoss
Interest expense3 months2018-01-01 to 2018-03-31$304us-gaap:InterestExpense
Net income3 months2018-01-01 to 2018-03-31−$2.4mus-gaap:NetIncomeLoss
Operating cash flow3 months2018-01-01 to 2018-03-31−$4.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2018-03-31$3.6mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-03-31$5.3mus-gaap:AssetsCurrent
Total assetsAt period end2018-03-31$11.2mus-gaap:Assets
Current liabilitiesAt period end2018-03-31$4.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-03-31$5.9mus-gaap:Liabilities
Shareholders' equityAt period end2018-03-31$5.3mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001144204-18-027296. Last ingested by Listed: Nov 12, 2026, 17:43 ET. Listed shows no prices and gives no investment advice.